The BU ADC is participating in a large new clinical
trial designed to evaluate the effectiveness
of a new medication in slowing the progression of
Alzheimer’s disease (AD). The BU ADC is one of
approximately 100 sites participating in this multi-center study sponsored by Myriad
Pharmaceuticals. Dr. Robert C. Green and Dr. Alan
Mandell are co-directors of the study at its BU site.
The study medication, Flurizan, is a compound
derived from a non-steroidal anti-inflammatory drug
(NSAID) called flurbiprofen. It has been shown in
preliminary studies to reduce brain levels of amyloid-
beta-42, a toxic protein that is thought to be a
primary cause of AD. Dr. Green recently commented
on the study: “I am very excited about this new
medication, as it holds much promise as a treatment
to slow AD. Flurizan has no prominent side effects
and, unlike currently approved treatments for AD, it
directly targets the amyloid problem.”
Individuals 55 years or older who live in the community,
have mild to moderate AD, and have a reliable
caregiver are encouraged to participate.
For further information on the study, please contact
Mayuri Thakuria at 617-638-5619 or
hazarika@bu.edu.
|
